1 to 10 of 705
Sort by

Library Entry
Defining current gaps in quality measures for cancer immunotherapy: consensus report from the Society for Immunotherapy of Cancer (SITC) 2019 Quality Summit

Quality measures are important because they can help improve and standardize the delivery of cancer care among healthcare providers and across tumor types. In an environment characterized by a rapidly shifting immunotherapeutic landscape and lack of associated long-term outcome data, defining...

Library Entry
Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study

Progression after high-dose melphalan with autologous stem cell transplantation (ASCT) in multiple myeloma (MM) may be due in part to immune dysfunction. Regulatory T (Treg) cells reconstitute rapidly after ASCT and inhibit immune responses against myeloma cells. The authors performed a...

Library Entry
Non-thermal histotripsy tumor ablation promotes abscopal immune responses that enhance cancer immunotherapy

Developing the ability to use tumor-directed therapies to trigger potentially therapeutic immune responses against cancer antigens remains a high priority for cancer immunotherapy. The authors hypothesized that histotripsy, a novel non-invasive, non-thermal ablation modality that uses ultrasound...

Library Entry
Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity

Ovarian cancers often contain significant numbers of tumor-infiltrating lymphocytes (TILs) that can be readily harnessed for adoptive T-cell therapy (ACT). However, the immunosuppressive ovarian tumor microenvironment and lack of tumor reactivity in TILs can limit the effectiveness of the...

Library Entry
NF-κB p50-deficient immature myeloid cell (p50-IMC) adoptive transfer slows the growth of murine prostate and pancreatic ductal carcinoma

Macrophages and dendritic cells lacking the transcription factor nuclear factor kappa B p50 are skewed toward a proinflammatory phenotype, with increased cytokine expression and enhanced T cell activation; additionally, murine melanoma, fibrosarcoma, colon carcinoma, and glioblastoma grow slower...

Web Page

January 2020 JITC Reading List January 2020 The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC’s Commentary/editorials Section Editor, Christian Capitini, MD. “Trans-endocytosis of intact IL-15Ralpha–IL-15 complex from presenting...

Web Page
JITC Digest January 2020

Inside this Issue: Letter from the Editor JITC Editor Picks Other Recent JITC ARTICLES Letter from the Editor Dear JITC Readers, Welcome to the first JITC Digest of 2020! The past decade has seen cancer immunotherapy advance to an incredible degree, and the pace of innovation is not...

Library Entry
Moving cancer immunotherapy forward through the Journal for ImmunoTherapy of Cancer (JITC)

Throughout the 6 years of the Journal for ImmunoTherapy of Cancer ’s ( JITC ) existence, the field of cancer immunotherapy has changed dramatically. In 2013, when the journal was founded, no programmed death (PD)-1 inhibitors had yet been approved by the Food and Drug Administration (FDA); the...

Library Entry
Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis

The monoclonal antibody (mAb) trastuzumab is part of the standard of care for patients with human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer. Antibody-dependent cell-mediated phagocytosis (ADCP) and cytotoxicity (ADCC) are major mechanisms of action of the mAb...